RheumNow

RheumNow Live 2026 begins TOMORROW— and there’s still time to join us virtually from anywhere. As a virtual attende https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg […]

Study shows half of FL autonomous nurse practitioners practicing outside their scope of practice. FL law allows autonomo https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…

Always on exams, but I’ve never seen a case! JAMA Dermatology reviews Multicentric Reticulohistiocytosis – pt w/ multi https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…

ALTO: Long-Term Abatacept Outcomes in At-Risk RA Lancet Rheumatology has published the ALTO results – long term outcom https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…

Giant Cell Arteritis Outcomes in Canada A retrospective cohort study of patients with giant cell arteritis (GCA) demon https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…

ANA Pollution (2.06.2026) jjcush@gmail.com Fri, 02/06/2026 – 00:49 Education/ACR/EULAR Anti-Rheumatic Rx Autoinflammatory Drug Safety Fibromyalgia/Pain General Rheumatology Gout IL-23 IL-6

ACR Applauds Recent Gov’t Funding jjcush@gmail.com Thu, 02/05/2026 – 18:57

Hiring, Onboarding and Training APPs Tuesday Night Rheumatology: Hiring, Onboarding and Training APPs. Visit our Missi https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 02/05/2026

Which Fibromyalgia Drugs are Cost-Effective? A cost-effectiveness analysis compared FDA approved fibromyalgia (FM) dru https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 02/05/2026 – 16:00

SGLT2 Inhibitors in Gout – Better Outcomes, Fewer Meds Natalie McCormick, PhD (RACER Center, Mass General Brigham), le https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john…

NEXT STEPS: Karp and investigators are engaged in the MONA LISA study – Using smile Data and biospeciments – they

Take home points from his presentation. Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/kDFrGi7i https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 02/05/2026 –

SMILE enrollment hampered by COVID – yet failed to show a protective effect for HCQ in preventing SLE. Can you

The challenge may be that lupus has multiple endotypes with variable rates of progression/trajectories. Can you Prevent https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu,

REcently published SMILE study looked at the potential of HCQ (vs PBO) to prevent SLE in at risk people. Had

Factors that may augment future development of SLE – includes Vitamin D levels, poor sleep, EBV reactivation & socia https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg

Only a subset of incomplete lupus (ILE) will progress to SLE – betw 1 in 10 and 1 in 5.

Study of 286 RA pt finds comorbidity burden—particularly psychological comorbidity—was strongly associated with poor https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 02/05/2026 – 10:00

Can you Prevent SLE? Dr. David Karp lecturing at UTSW Showing that autoantibodies exist long before the onset of SLE

RA outcomes according to onset: typica RA vs undifferentiated inflam arthritis (UIA) or palindromic rheumatism (PR). P https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed,

DERM on RheumNow PODCAST (January 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg

Methotrexate intolerance in rheumatoid arthritis A current large rheumatoid arthritis (RA) cohort study from Cairo ass https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 02/04/2026

ALTO: Long-Term Abatacept Outcomes in At-Risk RA jjcush@gmail.com Wed, 02/04/2026 – 15:24

Giant Cell Arteritis Outcomes in Canada jjcush@gmail.com Wed, 02/04/2026 – 14:38

ALTO: Long-Term Abatacept Outcomes in At-Risk Rheumatoids jjcush@gmail.com Wed, 02/04/2026 – 15:24

Long term outcomes study of 22 pts w/ adult Stills. 16 (72.7%) completed LTE w/ mean observation 168.9 wks. 3/22